Is the Predictive Ability of Positron Emission Tomography After Neoadjuvant Treatment for Esophageal Cancer Ready for Prime-Time?

Monjazeb et al performed a single-institution, retrospective study of 163 patients with histologically confirmed stage I to IVa esophageal cancer to assess the utility of positron-emission tomography (PET) in delineating which patients would most likely benefit from esophagectomy after induction che...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in thoracic and cardiovascular surgery 2011, Vol.23 (2), p.87-88
Main Authors: Groth, Shawn S., MD, MSc, D'Cunha, Jonathan, MD, PhD
Format: Article
Language:English
Subjects:
Cardiothoracic Surgery
Chemoradiotherapy, Adjuvant
drug therapy
esophageal carcinoma
Esophageal Neoplasms - diagnostic imaging
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophagectomy
Humans
Neoadjuvant Therapy
Neoplasm Staging
Patient Selection
Positron-Emission Tomography
Predictive Value of Tests
radiotherapy
survival
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monjazeb et al performed a single-institution, retrospective study of 163 patients with histologically confirmed stage I to IVa esophageal cancer to assess the utility of positron-emission tomography (PET) in delineating which patients would most likely benefit from esophagectomy after induction chemoradiation therapy. They found that patients who achieve a PET complete response after definitive chemoradiation therapy had similar outcomes to patients treated with trimodal therapy and concluded that patients who achieve a PET complete response after induction therapy may not benefit from esophagectomy. Though their study is interesting, their results should be validated by a prospective trial before they are incorporated into clinical practice.
ISSN:1043-0679
1532-9488
DOI:10.1053/j.semtcvs.2011.04.007